STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing ® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9-months through September 30, 2013.
Revenues for the third quarter of 2013 totaled €768.0 thousand, up 14% compared to the third quarter of 2012. The substitution of paclitaxel by compounds of the “limus” family, deemed more efficient, on all coronary drug-eluting stents on the market may currently slow down the STENTYS paclitaxel-eluting stent’s entry into new accounts and has yielded a more moderate growth rate this quarter. The first clinical results from the STENTYS Sirolimus-eluting stent (“limus” family) will be presented on October 29, and its commercialization outside of the United States is expected after CE Mark approval by the end of 2014.
- Trends in quarterly and 9-month 2013 revenues*
|9 months||Quarterly - 3 months|
|€ thousands||9 months 2013||9 months 2012||% change||Q3 2013||Q3 2012||% change|
|* Data reviewed by statutory auditors|
Over the first nine months of the financial year, STENTYS recorded revenues of €2.4 million, up 32% compared to the same period in 2012.
- Healthy cash position
- Presentation of new clinical results at the TCT conference
- Upcoming financial results